Bovine Respiratory Disease (BRD) is a complex disease with many contributing factors—including stress that compromises the immune system. Even though there are many antimicrobial options for BRD, veterinarians and producers continue to look for new technology to treat BRD. Zelnate DNA Immunostimulant is a novel, non-antibiotic technology that enhances the animal’s natural defenses against BRD. Learn more about BRD
Zelnate is the first licensed immunostimulant that aids in the treatment of BRD associated with Mannheimia haemolytica.
Zelnate aids in the treatment of BRD due to Mannheimia haemolytica in cattle 4 months of age or older, when administered at the time of, or within 24 hours after, a perceived stressful event. View the complete product label
While vaccines work with the adaptive immune response to target specific pathogens, sometimes requiring days or weeks to develop, immunostimulants trigger a rapid and broad response to infection via the innate immune system.
The key difference between Zelnate and other immunostimulants lies in its revolutionary DNA-liposome complex. The Zelnate DNA has a unique code that mimics infection, causing the animal's immune system to recognize Zelnate as foreign. This jumpstarts the innate immune system in cattle. Watch the Zelnate MOA video >
Zelnate was demonstrated in research studies to significantly reduce lung lesions and mortality (death loss) in the face of clinical BRD (P < 0.05). The efficacy of Zelnate for BRD control (metaphylaxis) and BRD treatment (pull and treat) has also been verified in large-scale studies. See Zelnate research studies >
In field studies, there were no injection site lesions or adverse events observed with the use of Zelnate when used according to the label.
Zelnate is available in 5, 10 and 50 dose package sizes to meet the needs of operations of any size. With easy-to-follow mixing instructions, Zelnate is simple to implement into existing routine practices. Learn how to mix and administer Zelnate >